Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Double anti-B867-ADC
- Development stage
- Preclinical
- Lead developer
- Nanolattix
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Double anti-B867-ADC is a preclinical bispecific antibody-drug conjugate (ADC) being developed by Nanolattix for the treatment of malignant solid tumors. As a bispecific ADC, the molecule is engineered to recognize two different antigens or two distinct epitopes, which may enhance tumor selectivity and promote efficient internalization of the cytotoxic payload. This approach aims to improve the therapeutic index by concentrating the drug's effect within the tumor microenvironment while sparing healthy tissue. The specific targets associated with the B867 designation have not been publicly disclosed. The candidate is currently undergoing preclinical evaluation to support future clinical development.
- Other names
- Double anti-B867-ADC-Nanolattix-ADC-bispecific antibody-Malignant solid tumor
Beyond the preview
Go deeper on Double anti-B867-ADC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Double anti-B867-ADC.